GSK stock: Berenberg raises 2031 revenue forecast
Published on 11/16/2026 at 17:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSLong-term growth debate
- Berenberg raised its 2031 GSK revenue forecast to GBP 39 billion.
- Patent expiries and pipeline execution remain central risks for investors.
- GSK stock traded at 23.06 euros on Lang & Schwarz on Monday, November 16.
Berenberg has raised its 2031 revenue forecast for GSK to GBP 39 billion, according to AJ Bell, which cited a Shares Magazine report published on Thursday, November 12. The analyst move adds a fresh long-term growth angle after GSK's recent business-development and pipeline activity.
Forecast lifts growth focus
Berenberg said GSK's recent business-development momentum and pipeline progress are underappreciated by the market. Its new forecast is ahead of the average market expectation cited by AJ Bell and remains close to GSK's ambition to generate more than GBP 40 billion in annual revenue by 2031.
The assessment comes as GSK shifts more of its portfolio toward specialty medicines, including HIV, oncology, and respiratory treatments. The company is also working to replenish products exposed to future patent expiries, particularly in its HIV franchise.
Patent risk remains material
AJ Bell highlighted the staggered loss of exclusivity for dolutegravir between 2028 and 2033, with the largest impact expected toward the end of 2029. GSK is seeking to move patients toward long-acting cabotegravir-based treatments while advancing new launches across oncology and other specialty areas.
That strategy creates a demanding execution test. Higher research and development spending can weigh on near-term earnings even as a deeper late-stage pipeline supports the longer-term sales case.
Shares trade in evening session
GSK stock traded at 23.06 euros on Lang & Schwarz at 17:43 CET on Monday, November 16. The quote followed the latest investor focus on the company's valuation, pipeline delivery, and exposure to patent expiry.
GSK plc at a glance
- Company: GSK plc
- ISIN: GB00BN7SWP63
- Ticker: GSK
- Trading venue: Lang & Schwarz
- Quote: 23.06 euros on Monday, November 16, 2026, at 17:43 CET
- Analyst forecast: GBP 39 billion GSK revenue in 2031, according to Berenberg as reported by AJ Bell
Broader pharmaceutical-market conditions remain relevant for investors. Current market reports provide further market context.
